Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01890291
NCT01890291CompletedNot Applicable

Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea

GC Cell Corporation5 sites in 1 country162 target enrollmentStarted: June 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
162
Locations
5
Primary Endpoint
To evaluate recurrence-free survival
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
  • •Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.

Exclusion Criteria

  • •Patient who is incongruent to this clinical trial by sub-investigator's opinion.

Outcomes

Primary Outcomes

To evaluate recurrence-free survival

Time Frame: up to 3 years

Radiological test should be operated by dynamic CT(using 64 cut), dynamic MRI or by angiography.

Secondary Outcomes

  • To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.(up to 3 years)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (5)

Loading locations...

Similar Trials

Completed
Not Applicable
Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in KoreaHepatocellular Carcinoma
NCT06620510GC Cell Corporation230
Completed
Phase 2
Safety and Efficacy of "Immuncell-LC" in TACE TherapyCarcinoma, Hepatocellular
NCT02856815GC Cell Corporation76
Recruiting
Not Applicable
Clinical and Immunological Outcomes of Living and Deceased Donor TransplantationTransplant Recipient (Kidney)
NCT06759831IRCCS Azienda Ospedaliero-Universitaria di Bologna1,293
Active, not recruiting
Phase 1
Administration of 9valent vaccine against papillomavirus in HIV-positive wome
EUCTR2018-000228-33-BECHU Saint-Pierre200
Active, not recruiting
Not Applicable
PICAROS - Acalabrutinib RWE on 1L CLL in SpainChronic Lymphocytic Leukemia
NCT05999877AstraZeneca192